| human | Q5 |
| P11496 | CiNii Research ID | 1420564276164926208 |
| P9776 | e-Rad researcher number | 60340783 |
| P496 | ORCID iD | 0000-0002-3514-9927 |
| P27 | country of citizenship | Japan | Q17 |
| P108 | employer | Shimane University | Q1072918 |
| National Cancer Center | Q11421209 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q35266784 | (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients |
| Q35063808 | 5-Aminolevulinic acid protects against cisplatin-induced nephrotoxicity without compromising the anticancer efficiency of cisplatin in rats in vitro and in vivo |
| Q44650607 | 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer |
| Q92711829 | A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines |
| Q90617308 | A Genome-Wide Association Study Identifies Five Novel Genetic Markers for Trastuzumab-Induced Cardiotoxicity in Japanese Population |
| Q49618145 | A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin |
| Q28741189 | A comprehensive peptidome profiling technology for the identification of early detection biomarkers for lung adenocarcinoma |
| Q55479808 | A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing. |
| Q30829781 | A descriptive analysis of post-chemotherapy development of interstitial lung disease using spontaneous reporting data in Japan |
| Q90305805 | A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cycloph |
| Q43713510 | A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer |
| Q93385198 | A novel prediction score for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma |
| Q57790448 | A phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma |
| Q43045099 | A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904). |
| Q91292462 | A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes |
| Q33406863 | A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer |
| Q92884820 | A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study |
| Q88484374 | A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP |
| Q54683671 | A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer. |
| Q47146801 | A tissue microRNA signature that predicts the prognosis of breast cancer in young women |
| Q38679531 | Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer. |
| Q35066971 | Alternative two-step matrix application method for imaging mass spectrometry to avoid tissue shrinkage and improve ionization efficiency |
| Q50637909 | Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma. |
| Q33375874 | Amrubicin for non-small-cell lung cancer and small-cell lung cancer |
| Q97868455 | Annual report of the Japanese Breast Cancer Registry for 2017 |
| Q94566255 | Annual report of the Japanese Breast Cancer Society registry for 2016 |
| Q91736325 | Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data |
| Q89716965 | Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study |
| Q35713642 | Assessment of adverse events via a telephone consultation service for cancer patients receiving ambulatory chemotherapy |
| Q90835887 | BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma |
| Q92105344 | BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy |
| Q41286438 | Back with a vengeance: microvascular tumor embolism |
| Q47154315 | Baseline risk of recurrence in stage I-II endometrial carcinoma. |
| Q91820901 | Biomarker discordance between primary breast cancer and bone or bone marrow metastases |
| Q92139036 | Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography |
| Q48737984 | Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer |
| Q90655998 | Brain metastasis-related microRNAs in patients with advanced breast cancer |
| Q35407588 | Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier |
| Q42963494 | Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer |
| Q91841259 | CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study |
| Q92092126 | Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer |
| Q34316618 | Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy |
| Q43625604 | Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma |
| Q83732297 | Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy |
| Q38027060 | Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis. |
| Q91430716 | Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanes |
| Q42367352 | Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials |
| Q28483289 | Content analysis of oncology-related pharmaceutical advertising in a peer-reviewed medical journal |
| Q92718466 | Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130) |
| Q39193533 | Current status of medical oncology in Japan--reality gleaned from a questionnaire sent to designated cancer care hospitals |
| Q53051446 | Desmoplastic small round cell tumor with sphere-like clusters mimicking adenocarcinoma. |
| Q81403012 | Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer |
| Q34155027 | Diagnosis and management of pancreatic neuroendocrine tumor in von Hippel-Lindau disease |
| Q42806448 | Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification |
| Q38907890 | Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan |
| Q90439132 | Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors |
| Q40234556 | Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells |
| Q37544321 | Drug induced interstitial lung disease in oncology phase I trials. |
| Q47999034 | Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis. |
| Q94406731 | EXTH-50. DEVELOPMENT OF INVESTIGATOR INITIATED CLINICAL TRIAL OF TERT-TARGETING THERAPY USING ERIBULIN MESYLATE IN PATIENTS WITH RECURRENT GLIOBLASTOMA |
| Q51730243 | Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor. |
| Q47260008 | Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study |
| Q92202201 | Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial |
| Q89734122 | Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites |
| Q89004345 | Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study |
| Q39330537 | Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells |
| Q92107306 | Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts |
| Q42282683 | Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging. |
| Q38978972 | Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. |
| Q90919160 | Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults |
| Q39199929 | Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis |
| Q49130991 | Factors that affect the duration of the interval between the completion of palliative chemotherapy and death |
| Q53511600 | Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab. |
| Q84390387 | Feasibility and usefulness of the 'Distress Screening Program in Ambulatory Care' in clinical oncology practice |
| Q64083862 | Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study |
| Q93144123 | Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: a retrospective study |
| Q38653463 | Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy |
| Q92419508 | Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy |
| Q49787556 | Gene aberration profile of tumors of adolescent and young adult females. |
| Q36807462 | Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population |
| Q42860994 | Granulocyte-colony stimulating factor producing squamous cell carcinoma of the renal pelvis: a case report |
| Q98502243 | HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix |
| Q33400777 | Hematologic safety of breast cancer chemotherapies in patients with hepatitis B or C virus infection |
| Q95661040 | High-throughput functional evaluation of BRCA2 variants of unknown significance |
| Q33399573 | Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS. |
| Q82578462 | Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy |
| Q46240839 | Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy |
| Q57821079 | Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles |
| Q43148960 | Influence of suboptimal treatment in patients with mediastinal primary nonseminomatous germ cell tumors |
| Q92072322 | Insights Into Breast Cancer in the East vs the West: A Review |
| Q90419623 | Invasive breast cancers in adolescent and young adult women show more aggressive immunohistochemical and clinical features than those in women aged 40-44 years |
| Q50924898 | LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. |
| Q45174193 | Localized Fournier's gangrene of the penis: a case report |
| Q94555560 | Long Non-coding NR2F1-AS1 is Associated with Tumor Recurrence in Estrogen Receptor-positive breast cancers |
| Q48202591 | Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. |
| Q45991888 | Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer. |
| Q35813557 | Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1. |
| Q33286516 | Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles |
| Q38444869 | Molecular imaging using PET for breast cancer |
| Q101121966 | Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer |
| Q24299807 | Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer |
| Q35125899 | Nucleostemin expression in invasive breast cancer |
| Q39815353 | Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer |
| Q80473371 | Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience |
| Q89115082 | PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system |
| Q37959375 | Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer |
| Q38817753 | Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. |
| Q42694484 | Pancreatic involvement in Japanese patients with von Hippel-Lindau disease: results of a nationwide survey |
| Q33873330 | Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy |
| Q93147870 | Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study |
| Q92641644 | Peripheral neuropathy from paclitaxel: risk prediction by serum microRNAs |
| Q64990605 | Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function. |
| Q41595492 | Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors |
| Q62787735 | Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B |
| Q98905988 | Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer |
| Q84792085 | Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer |
| Q33418305 | Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer |
| Q45991139 | Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors. |
| Q79394815 | Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses |
| Q80789081 | Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer |
| Q54982557 | Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer. |
| Q92261136 | Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours |
| Q33384319 | Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer |
| Q33392831 | Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study |
| Q50533001 | Photodynamic diagnosis of positive margin during radical prostatectomy: preliminary experience with 5-aminolevulinic acid. |
| Q47213748 | Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide |
| Q41557798 | Plasma protoporphyrin IX following administration of 5-aminolevulinic acid as a potential tumor marker |
| Q93077429 | Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer |
| Q47223679 | Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. |
| Q36551375 | Primary yolk sac tumor of the omentum: a case report and literature review |
| Q91709068 | Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma |
| Q46046634 | Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers |
| Q49578351 | Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site |
| Q47155730 | Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy |
| Q33738990 | Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. |
| Q50541987 | Re-evaluation of histological type by immunohistochemical and genetic study of transcription factors (TFE3 and TFEB) of VHL gene mutation-negative clear cell renal cell carcinoma and other special types of renal tumor. |
| Q93089567 | Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan |
| Q104684498 | Regulatory and Operational Challenges in Conducting Asian International Academic Trial for Expanding the Indications of Cancer Drugs |
| Q46036131 | Relapse with malignant transformation after chemotherapy for primary mediastinal seminoma: case report. |
| Q97554781 | Reply to T.J.A. Dekker |
| Q90610564 | Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation |
| Q49170846 | SHISA2 enhances the aggressive phenotype in prostate cancer through the regulation of WNT5A expression |
| Q91450176 | SMARCB-1 deficient squamous cell carcinoma of a mediastinal cyst |
| Q34319619 | SNRPE is involved in cell proliferation and progression of high-grade prostate cancer through the regulation of androgen receptor expression |
| Q64066298 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer |
| Q47644645 | Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study |
| Q82059592 | Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy |
| Q53248857 | Second-line chemotherapy in patients with primary unknown cancer. |
| Q93349831 | Serum miRNA-based Prediction of Axillary Lymph Node Metastasis in Breast Cancer |
| Q93099694 | Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer |
| Q96129132 | Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults |
| Q80199854 | Skeletal metastases in non-small cell lung cancer: a retrospective study |
| Q39870904 | Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer |
| Q90711534 | Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130) |
| Q43234037 | Successful response of reccurent adult wilms' tumor to multiagent chemotherapy |
| Q39114679 | Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience |
| Q99590854 | Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment |
| Q48161267 | Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer. |
| Q40001439 | Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase |
| Q47339267 | TERT promoter hotspot mutations in breast cancer. |
| Q90659989 | Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors |
| Q91967571 | Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients |
| Q91322820 | The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site |
| Q50079861 | The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma |
| Q89974548 | The Use of PET/CT and Bone Marrow Aspiration/Biopsy in Initial Staging Evaluation of Adolescent and Adult Ewing Sarcomas |
| Q53677254 | The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. |
| Q34472128 | The expression and clinical significance of ribophorin II (RPN2) in human breast cancer |
| Q84228894 | The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors |
| Q37834381 | The notorious "drug lag" for oncology drugs in Japan |
| Q30947633 | The ubiquitin-like molecule interferon-stimulated gene 15 is overexpressed in human prostate cancer. |
| Q90661144 | Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma |
| Q46490446 | Therapy-related acute promyelocytic leukemia caused by hormonal therapy and radiation in a patient with recurrent breast cancer |
| Q91873787 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer |
| Q64109775 | Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study |
| Q64109771 | Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study |
| Q80162294 | Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts |
| Q90434476 | Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study |
| Q96294058 | Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma |
| Q90122167 | Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data |
| Q42488113 | Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer |
| Q55167238 | Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. |
| Q37408139 | Use of Cox's Cure Model to Establish Clinical Determinants of Long-Term Disease-Free Survival in Neoadjuvant-Chemotherapy-Treated Breast Cancer Patients without Pathologic Complete Response. |
| Q51540828 | Use of squamous cell carcinoma antigen as a biomarker of chemotherapy response in patients with metastatic cervical carcinoma. |
| Q64047615 | Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma |
| Q48301412 | Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET. |
| Q99616873 | Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging |
| Q47286758 | Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity. |
| Q90483214 | Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease |
| Q34717001 | Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival |
| Q84200430 | [A case of carcinoid tumor arising from a horseshoe kidney] |
| Q84391242 | [A case of retroperitoneal solitary fibrous tumor] |
| Q95584455 | [Anti-angiogenic therapy in breast cancer] |
| Q84759161 | [Clinical status of Von Hippel-Lindau disease associated pheochromocytoma in Japan: a national epidemiologic survey] |
| Q64043436 | [Experience in the treatment of eight cases of Fournier's gangrene] |
| Q86641310 | [First experiences of laparoscopic radical cystectomy] |
| Q90829514 | [Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma] |
| Q92757151 | [LAPAROSCOPIC RADICAL PROSTATECTOMY OF 926 PATIENTS AT THE HIROSHIMA ENDOUROLOGICAL ASSOCIATION] |
| Q83863271 | [The clinical value of 3 tesla diffusion-weighted magnetic resonance imaging in the diagnosis of prostate cancer] |
| Q84859453 | [The role to be played by the specialty of tumor chemotherapy: a discussion] |
| Q52949176 | [Undifferentiated Prostate Cancer Treated with Radiation Therapy]. |
| Q55310828 | ＜Editors' Choice＞ Practice management for elderly patients with breast cancer; Findings from a survey by the Japan Breast Cancer Study Group. |
Search more.